CAERPHILLY BLENDERS LIMITED

1. Risk Rating: LOW

Justification: The company is officially classified as dormant with a SIC code of 99999, meaning it is not actively trading and has no significant financial transactions. Furthermore, the company is fully compliant with regulatory filing requirements, with no overdue accounts or confirmation statements. The inherent risk of a dormant, compliant entity is minimal, though its risk profile is entirely dependent on the financial health of its corporate parent.

2. Key Concerns

• Complete Dependence on Parent Entity: The company is wholly controlled by Biological Preparations Limited, which holds more than 75% of the shares and voting rights, and possesses the right to appoint and remove directors. Any financial distress or insolvency at the parent level could directly impact the assets or future status of this entity.
• Lack of Financial Visibility: As a dormant company, detailed financial statements (Profit & Loss, cash flow, detailed balance sheet) are not available. While the share capital is stated at £50,000, the absence of current asset and liability data makes it impossible to independently verify the true net asset position or identify any latent liabilities not captured by the dormant status.
• Duplicate PSC Registration: Biological Preparations Limited is listed twice with identical control thresholds in the People with Significant Control register. While likely an administrative anomaly, it raises a minor concern regarding the precision of the company's internal statutory record-keeping.

3. Positive Indicators

• Regulatory Compliance: The company's accounts and confirmation statements are up to date, with no filings currently marked as overdue. This indicates competent administrative oversight.
• Corporate Backing: Having a corporate parent with over 75% control provides structural stability. The parent entity is presumably covering the ongoing maintenance costs (e.g., filing fees) of this dormant subsidiary.
• Longevity: Incorporated in 2005, the company has maintained an active status for nearly two decades, suggesting it is a long-standing, stable part of a wider corporate group structure rather than a transient or shell entity.

4. Due Diligence Notes

• Parent Company Analysis: A thorough assessment of Biological Preparations Limited is essential. The risk profile of a dormant subsidiary is inextricably linked to its parent; therefore, the parent's solvency, liquidity, and creditworthiness must be reviewed to understand any contingent risks.
• Strategic Purpose: Investigate the commercial rationale for maintaining this dormant entity. Dormant companies are frequently held for intellectual property holding, asset protection, or as a pre-positioned vehicle for future acquisitions. Understanding its intended purpose will clarify if any future liabilities are anticipated.
• PSC Register Rectification: The duplicate PSC entry for Biological Preparations Limited should be flagged. It would be prudent to request confirmation that the company's internal statutory registers are accurate and reflect only a single controlling entity.